Tumorigenesis in mammals is driven by inherited genetic variants, environmental factors and random errors during normal DNA replication that lead to cancer-causing mutations. These factors initiate uncontrolled cellular proliferation and disrupt the regulation of critical checkpoints. A few mammalian species possess unique protective mechanisms that enable them to resist widespread cancer development and achieve longevity. Tissue-specific tumor protection adds another layer of complexity to this diversity. Breast cancer is a leading cause of human mortality, particularly among females. Driven by the need for new strategies in treatment and prevention, this opinion article explores and supports the idea that herbivores are more resistant to mammary cancer than carnivores and omnivores. This diversity has occurred despite the remarkably similar basic mammary biology. Herbivores' meatless diet cannot explain the differences in cancer resistance, which have accompanied species segregation since the Jurassic era. To investigate the causes of this diversity, the characteristics of tumorigenesis in the human breast-and to a lesser extent in other carnivores-have been compared with data from retrospective analyses of bovine mammary tumor development across various locations over the past century. Well-established genomic, cellular, and systemic triggers of breast cancer exhibit different, or less pronounced tissue-specific activity in the bovine mammary gland, accompanied by novel bovine-specific protective mechanisms. Together, these factors contribute to the near absence of breast cancer in bovines and offer a basis for developing future anticancer strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885404 | PMC |
http://dx.doi.org/10.1007/s10911-025-09578-4 | DOI Listing |
FASEB J
March 2025
Department of Oncology, The Central Hospital of Yongzhou, Yongzhou, Hunan, China.
The ribophorin family, including RPN1, has been associated with tumor progression, but its specific role in pan-cancer dynamics remains unclear. Using data from TCGA, GTEx, and Ualcan databases, we investigated the relationship of RPN1 with prognosis, genomic alterations, and epigenetic modifications across various cancers. Differential analysis revealed elevated RPN1 expression in multiple cancer types, indicating a potential prognostic value.
View Article and Find Full Text PDFCancer Med
March 2025
Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.
Introduction: Distress is common among cancer patients, especially those undergoing surgery. However, no study has systematically analyzed distress trends in this population. The purpose of this study was to systematically review perioperative rates of distress, as well as differences across cancer types, in cancer patients undergoing surgical intervention.
View Article and Find Full Text PDFFASEB J
March 2025
Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin, China.
Breast cancer (BC) is one of the most common malignant tumors among women, accounting for 24.5% of all cancer cases and leading to 15.5% of cancer-related mortality.
View Article and Find Full Text PDFJ Biomol Struct Dyn
March 2025
Applied Organic Chemistry Department, National Research Center, Dokki, Egypt.
The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-]pyridine derivatives (), confirmed spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay.
View Article and Find Full Text PDFAdv Healthc Mater
March 2025
Department of Ultrasound, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361000, P. R. China.
The abnormal tumor mechanical microenvironment due to specific cancer-associated fibroblasts (CAFs) subset and low tumor immunogenicity caused by inefficient conversion of active chemotherapeutic agents are two key obstacles that impede patients with desmoplastic tumors from achieving stable and complete immune responses. Herein, it is demonstrated that FAP-αCAFs-induced stromal stiffness accelerated tumor progression by precluding cytotoxic T lymphocytes. Subsequently, a cascade-responsive nanoprodrug capable of re-educating FAP-αCAFs and amplifying tumor immunogenicity for potentiated cancer mechanoimmunotherapy is ingeniously designed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!